PharmaShots Interview: Paul Brennan Shares Insights on NVG-291 and its Interim Data for the Treatment of Neurodegenerative Diseases
In an interview with PharmaShots, Paul Brennan, President, CEO & Director at NervGen shared his views on the interim data of NVG-291 for the treatment […]